Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 1;28(9):2298-2304.
doi: 10.1093/annonc/mdx294.

Oncologist use and perception of large panel next-generation tumor sequencing

A M Schram  1 , D Reales  2 , J Galle  2 , R Cambria  2 , R Durany  3 , D Feldman  1   4 , E Sherman  1   4 , J Rosenberg  1   4 , G D'Andrea  1   4 , S Baxi  1   4 , Y Janjigian  1   4 , W Tap  1   4 , M Dickler  1   4 , J Baselga  1   4   5   6 , B S Taylor  5   6   7 , D Chakravarty  6 , J Gao  6 , N Schultz  6   7 , D B Solit  1   4   5   6 , M F Berger  6   8 , D M Hyman  1   4
Affiliations

Oncologist use and perception of large panel next-generation tumor sequencing

A M Schram et al. Ann Oncol. .

Abstract

Background: Genomic profiling is increasingly incorporated into oncology research and the clinical care of cancer patients. We sought to determine physician perception and use of enterprise-scale clinical sequencing at our center, including whether testing changed management and the reasoning behind this decision-making.

Patients and methods: All physicians who consented patients to MSK-IMPACT, a next-generation hybridization capture assay, in tumor types where molecular profiling is not routinely performed were asked to complete a questionnaire for each patient. Physician determination of genomic 'actionability' was compared to an expertly curated knowledgebase of somatic variants. Reported management decisions were compared to chart review.

Results: Responses were received from 146 physicians pertaining to 1932 patients diagnosed with 1 of 49 cancer types. Physicians indicated that sequencing altered management in 21% (331/1593) of patients in need of a treatment change. Among those in whom treatment was not altered, physicians indicated the presence of an actionable alteration in 55% (805/1474), however, only 45% (362/805) of these cases had a genomic variant annotated as actionable by expert curators. Further evaluation of these patients revealed that 66% (291/443) had a variant in a gene associated with biologic but not clinical evidence of actionability or a variant of unknown significance in a gene with at least one known actionable alteration. Of the cases annotated as actionable by experts, physicians identified an actionable alteration in 81% (362/445). In total, 13% (245/1932) of patients were enrolled to a genomically matched trial.

Conclusion: Although physician and expert assessment differed, clinicians demonstrate substantial awareness of the genes associated with potential actionability and report using this knowledge to inform management in one in five patients.

Clinical trial number: NCT01775072.

Keywords: next-generation sequencing; precision medicine; targeted therapy; tumor sequencing.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Genomically matched clinical trials. (A) Characterization of alterations used to genomically match patients to targeted therapy across tumor types. (B) Distribution of matching alterations by level of evidence. (C) Rate of genomic matching to clinical trials over time.
Figure 2.
Figure 2.
Physician determination of actionability stratified by level of evidence.
See this image and copyright information in PMC

References

    1. Sholl LM, Do K, Shivdasani P. et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 2016; 1: e87062. - PMC - PubMed
    1. Stockley TL, Oza AM, Berman HK. et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 2016; 8: 109.. - PMC - PubMed
    1. Cheng DT, Mitchell TN, Zehir A. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor. Mol Oncol J Mol Diagn 2015; 17: 251–264. - PMC - PubMed
    1. Hyman DM, Solit DB, Arcila ME. et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today 2015; 20: 1422–1428. - PMC - PubMed
    1. Chakravarty D, Gao J, Phillips S. et al. OncoKB: a precision oncology knowledge base. J Clin Oncol 2017; 1: 1–16. - PMC - PubMed

MeSH terms

Associated data